同时使用原子抑制剂与Palbociclib片用于转移性乳腺癌的效果
Timothy Schieber1, Samantha Steele2, Stephanie Collins1
1Pharmacy Department, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH.
Clinical breast cancer
|June 9, 2023
概括
与palbociclib片同时使用质子抑制剂 (PPI) 并没有显著影响转移性乳腺癌 (MBC) 患者的无进展生存期 (PFS). 这一发现与早期使用palbociclib囊的研究有所不同,这表明与药片形式的组合更安全.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 帕尔博西克利布是HR+/HER2-转移性乳腺癌 (MBC) 的关键治疗方法.
- 之前的研究表明,使用质子抑制剂 (PPI) 降低了用palbociclib囊的无进展生存期 (PFS).
- 2020年批准的Palbociclib片没有PPI使用限制,需要进一步调查.
研究的目的:
- 为了评估同时使用质子抑制剂 (PPI) 对接受 HR+/HER2- MBC. palbociclib片剂的患者PFS的影响.
- 为了比较使用PPI和不使用PPI与palbociclib片同时使用的患者之间的PFS,整体存活率 (OS) 和不良事件.
主要方法:
- 对82名HR+/HER2-MBC患者的回顾性评估,这些患者接受了palbociclib药片治疗.
- 患者被分为"不使用PPI"或"使用PPI" (>50%的治疗时间).
- 主要终点是无进展生存 (PFS);次要终点包括整体生存 (OS) 和不良事件.
主要成果:
- 在没有使用PPI的组 (20.6个月) 和使用PPI的组 (21.0个月) (P = 0.95) 之间没有观察到PFS中位数的显著差异.
- 在这两组中均未达到平均整体存活期 (OS).
- 两只手臂的不良事件是可比的.
结论:
- 与palbociclib片同时使用质子抑制剂 (PPI) 并没有显著降低HR+/HER2-转移性乳腺癌 (MBC) 患者的无进展生存期 (PFS).
- 这些发现表明,PPI可以安全地与palbociclib片一起使用,与之前对palbociclib囊的担忧不同.
- 进一步的研究可能会探索这种差异背后的机制,并证实长期的结果.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
475
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
475
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
407
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
407
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
569
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
569
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
523
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
523
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
255
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
255
Drugs for Treatment of Constipation-Predominant IBS
236
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
236


